Immix Biopharma is trading at $8.79, down 5.03%, amid biotech-sector weakness; XBI’s decline offers a plausible, but unconfirmed, explanation. - No new company-specific announcement or catalyst was identified on October 13; the latest reported company news was its October 5 conference participation announcement. - Broader indexes were nearly flat, making general market weakness a less explanatory factor than the biotech-sector decline.